Page 680 - Read Online
P. 680

Page 12 of 15                            Abe et al. J Cancer Metastasis Treat 2020;6:51  I  http://dx.doi.org/10.20517/2394-4722.2020.117

               Consent for publication
               Not applicable.


               Copyright
               © The Author(s) 2020.


               REFERENCES
               1.   Burningham Z, Hashibe M, Spector L, Schiffman JD. The epidemiology of sarcoma. Clin Sarcoma Res 2012;2:14.
               2.   Hui JY. Epidemiology and etiology of sarcomas. Surg Clin North Am 2016;96:901-14.
               3.   Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020;70:7-30.
               4.   Jo VY, Fletcher CDM. WHO classification of soft tissue tumours: an update based on the 2013 (4th) edition. Pathology 2014;46:95-104.
               5.   Blay JY, Ray-Coquard I. Sarcoma in 2016: evolving biological understanding and treatment of sarcomas. Nat Rev Clin Oncol
                   2017;14:78-80.
               6.   Schaefer IM, Cote GM, Hornick JL. Contemporary sarcoma diagnosis, genetics, and genomics. J Clin Oncol 2018;36:101-10.
               7.   Casali PG, Bielack S, Abecassis N, et al. Bone sarcomas: ESMO-PaedCan-EURACAN clinical practice guidelines for diagnosis,
                   treatment and follow-up. Ann Oncol 2018;29:iv79-95.
               8.   von Mehren M, Randall RL, Benjamin RS, et al. Soft tissue sarcoma, version 2.2018, NCCN clinical practice guidelines in oncology. J
                   Natl Compr Canc Netw 2018;16:536-63.
               9.   Koliou P, Karavasilis V, Theochari M, Pollack SM, Jones RL, Thway K. Advances in the treatment of soft tissue sarcoma: focus on
                   eribulin. Cancer Manag Res 2018;10:207-16.
               10.  Assi T, Kattan J, El Rassy E, et al. A comprehensive review of the current evidence for trabectedin in advanced myxoid liposarcoma.
                   Cancer Treat Rev 2019;72:37-44.
               11.  Dufresne A, Brahmi M, Karanian M, Blay JY. Using biology to guide the treatment of sarcomas and aggressive connective-tissue
                   tumours. Nat Rev Clin Oncol 2018;15:443-58.
               12.  Nacev BA, Jones KB, Intlekofer AM, et al. The epigenomics of sarcoma. Nat Rev Cancer 2020;20:608-23.
               13.  Scotlandi K, Hattinger CM, Pellegrini E, Gambarotti M, Serra M. Genomics and therapeutic vulnerabilities of primary bone tumors. Cells
                   2020;9:968.
               14.  Hall F, Villalobos V, Wilky B. Future directions in soft tissue sarcoma treatment. Curr Probl Cancer 2019;43:300-7.
               15.  Du XH, Wei H, Zhang P, Yao WT, Cai QQ. Heterogeneity of soft tissue sarcomas and its implications in targeted therapy. Front Oncol
                   2020;10:564852.
               16.  Lee DY, Staddon AP, Shabason JE, Sebro R. Phase I and phase II clinical trials in sarcoma: implications for drug discovery and
                   development. Cancer Med 2019;8:585-92.
               17.  Miwa S, Yamamoto N, Hayashi K, Takeuchi A, Igarashi K, Tsuchiya H. Therapeutic targets for bone and soft-tissue sarcomas. Int J Mol
                   Sci 2019;20:170.
               18.  Cormier KW, Woodgett JR. Recent advances in understanding the cellular roles of GSK-3. F1000Res 2017;6:167.
               19.  Patel P, Woodgett JR. Glycogen synthase kinase-3: a kinase for all pathways? Curr Top Dev Biol 2017;123:277-302.
               20.  Beurel E, Grieco SF, Jope RS. Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases. Pharmacol Ther 2015;148:114-31.
               21.  Hoffmeister L, Diekmann M, Brand K, Huber R. GSK3: a kinase balancing promotion and resolution of inflammation. Cells 2020;9:820.
               22.  Khan I, Tantray MA, Alam MS, Hamid H. Natural and synthetic bioactive inhibitors of glycogen synthase kinase. Eur J Med Chem
                   2017;125:464-77.
               23.  Saraswati AP, Ali Hussaini SM, Krishna NH, Babu BN, Kamal A. Glycogen synthase kinase-3 and its inhibitors: potential target for
                   various therapeutic conditions. Eur J Med Chem 2018;144:843-58.
               24.  Zhu J, Wu Y, Wang M, et al. Integrating machine learning-based virtual screening with multiple protein structures and bio-assay
                   evaluation for discovery of novel GSK3 inhibitors. Front Pharmacol 2020;11:566058.
               25.  McCubrey JA, Davis NM, Abrams SL, et al. Diverse roles of GSK-3: tumor promoter-tumor suppressor, target in cancer therapy. Adv
                   Biol Regul 2014;54:176-96.
               26.  Nagini S, Sophia J, Mishra R. Glycogen synthase kinases: moonlighting proteins with theranostic potential in cancer. Semin Cancer Biol
                   2019;56:25-36.
               27.  Miyashita K, Nakada M, Shakoori A, et al. An emerging strategy for cancer treatment targeting aberrant glycogen synthase kinase 3β.
                   Anticancer Agents Med Chem 2009;9:1114-22.
               28.  Domoto T, Pyko IV, Furuta T, et al. Glycogen synthase kinase-3β is a pivotal mediator of cancer invasion and resistance to therapy.
                   Cancer Sci 2016;107:1363-72.
               29.  Walz A, Ugolkov A, Chandra S, et al. Molecular pathways: revisiting glycogen synthase kinase-3β as a target for the treatment of cancer.
                   Clin Cancer Res 2017;23:1891-7.
               30.  Domoto T, Uehara M, Bolidong D, Minamoto T. Glycogen synthase kinase 3β in cancer biology and treatment. Cells 2020;9:1388.
               31.  Dmitry I. Osolodkin, Vladimir A. Palyulin, Nikolay S. Zefirov. Glycogen synthase kinase 3 as an anticancer drug target: novel
                   experimental findings and trends in the design of inhibitors. Curr Pharm Des 2013;19:665-79.
               32.  Sahin I, Eturi A, De Souza A, et al. Glycogen synthase kinase-3 beta inhibitors as novel cancer treatments and modulators of antitumor
   675   676   677   678   679   680   681   682   683   684   685